AOD-9604 vs Cagrilintide vs CJC-1295

A three-way comparison to help you find the right peptide for your research goals.

AOD-9604

AOD-9604 is a modified fragment of human growth hormone (HGH fragment 176-191). It was developed to have the fat-reducing effects of growth hormone without the adverse effects on blood sugar or growth.

Full details →

Cagrilintide

Cagrilintide is a long-acting amylin analog in development, showing promising results when combined with semaglutide (CagriSema). Amylin is a hormone co-secreted with insulin that promotes satiety.

Full details →

CJC-1295

CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH) that stimulates the pituitary gland to produce more growth hormone.

Full details →

Side-by-Side Comparison

Aspect	AOD-9604	Cagrilintide	CJC-1295
Dose Range	300 mcg–500 mcg	300 mcg–4.5 mg	1 mg–2 mg
Frequency	1x daily	Less than daily	Less than daily
Cycle Length	12–24 weeks	26–68 weeks	8–12 weeks
Route	subcutaneous	subcutaneous	subcutaneous
Mechanism	Stimulates lipolysis (fat breakdown) and inhibits lipogenesis (fat accumulation) without affecting blood sugar or growth. Works specifically on adipose tissue through a mechanism independent of GH receptors.	Activates amylin receptors (calcitonin receptor with RAMP proteins) to slow gastric emptying, suppress glucagon secretion, and reduce food intake through central satiety mechanisms distinct from GLP-1.	CJC-1295 binds to GHRH receptors in the pituitary, triggering increased production and release of growth hormone. The DAC (Drug Affinity Complex) version extends half-life significantly.
Typical Dosage	Research dosing typically ranges from 250-500mcg daily, often split into morning and afternoon doses. Some protocols use higher doses up to 1mg.	Clinical trials: 2.4mg weekly as monotherapy or in combination with semaglutide 2.4mg (CagriSema). Optimal dosing still being determined.	CJC-1295 DAC: 1-2mg weekly. CJC-1295 no DAC (Mod GRF 1-29): 100-300mcg 2-3 times daily.
Administration	Subcutaneous injection, typically in the abdominal area. Best administered on an empty stomach. Can be combined with exercise for enhanced effects.	Subcutaneous injection once weekly. Currently only available in clinical trials - not yet FDA approved.	Subcutaneous injection, often combined with a GHRP like Ipamorelin for synergistic effects. Best administered before sleep or fasted.
Side Effects	Generally well-tolerated. May cause headaches, injection site reactions, or temporary lethargy. Does not affect blood glucose like full GH.	Nausea, vomiting, diarrhea, constipation similar to other incretin-based therapies. Combination with semaglutide may increase GI effects initially.	Water retention, tingling in extremities, potential increase in cortisol and prolactin levels.
Best For	Fat Loss	Fat Loss	Muscle Growth Fat Loss Sleep Quality